Kevin Skol has 20 plus years of experience in the pharmaceutical industry, primarily in business and corporate development, alliance management, strategy, competitive intelligence, and licensing. He previously worked at RNA based companies Ionis Pharmaceuticals and Digital Gene Technologies and at specialty pharmaceutical companies Elan Corporation and Valeant Pharmaceuticals. At Ionis he led business development and licensing efforts that resulted in major pharmaceutical partnerships with Astra Zeneca, Bayer, Roche, Janssen, Novartis, and Biogen.  Most recently he led the Arcturus business development team in the closing of several vaccine collaborations with the Vingroup in Vietnam, Israel and CSL Seqirus.  The combined transaction value of collaborative agreements and partnerships which he led throughout his career is estimated at over $4 billion. Mr. Skol previously served on the board of directors at Ingredient Innovations International (3i) which was subsequently acquired.  Mr. Skol graduated with a B.A. from Yale University and has an MBA from Harvard Business School.